Navigation Links
Boston Scientific Welcomes Revised Outlook From Fitch Ratings
Date:6/9/2008

NATICK, Mass., June 9 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today welcomed an announcement by Fitch Ratings that it has revised its Rating Outlook on the Company, to Stable from Negative. Fitch also reaffirmed the Company's long-term credit rating of BB+.

Fitch said the revised Outlook is supported by the progress Boston Scientific is making toward stabilizing its drug-eluting stent and cardiac rhythm management businesses, while paying down debt in the process. The Company has paid down $1.7 billion of debt during the past 12 months.

Fitch added that it expects Boston Scientific's leverage will decline further in the intermediate term through increased cash flow growth and debt reduction.

"We welcome this revised outlook and see it as another indication that we are moving in the right direction in a number of key areas," said Sam Leno, Chief Financial Officer of Boston Scientific. "The Fitch action also confirms that our expense and head count reduction plan is being executed effectively and is helping strengthen our financial position."

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: http://www.bostonscientific.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our financial performance, our programs to increase shareholder value, new product approvals, our expense reduction initiatives, our capital needs and expenditures, potential acquisitions and divestitures, our debt repayment strategy, our operational strategy, our growth strategy, market recovery and our market position. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

CONTACT: Paul Donovan

508-650-8541 (office)

508-667-5165 (mobile)

Media Relations

Boston Scientific Corporation

Larry Neumann

508-650-8696 (office)

Investor Relations

Boston Scientific Corporation


'/>"/>
SOURCE Boston Scientific Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Boston Scientific to Participate in Goldman Sachs Conference
2. Boston Scientific Announces CEO Jim Tobin to Extend Tenure
3. NanoLogix Inc. to Present at The American Society for Microbiology (ASM) General Meeting in Boston; Announces Product Line and Provides Operations Update
4. Boston Scientific Completes Acquisition of CryoCor
5. Boston Scientific Announces Launch of Expanded Size Range of FilterWire EZ(TM) Embolic Protection System
6. Boston Scientific Announces FDA Approval of New Heart Failure Lead
7. Boston Scientifics SpyGlass(R) Direct Visualization System to Be Prominently Featured at Digestive Disease Week(R)
8. Boston Scientific Announces Program to Analyze Latitude(R) Patient Monitoring Data
9. Boston Scientific Announces European Approval and Market Launch of New Family of Advanced Pacemakers
10. WIPO Panel Rules Boston Scientific Liberte(R) and TAXUS(R) Liberte(R) Stents Do Not Infringe Medinol Patents
11. Fraunhofer and Boston University Hosted Prestigious SME Tour
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Apellis ... Phase 1 clinical trials of its complement C3 ... single and multiple ascending dose studies designed to ... (PD) of subcutaneous injection in healthy adult volunteers. ... (SC) either as a single dose (ranging from ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance ... consulting, provides a free webinar on Performing Quality Investigations: Getting to ... 12pm CT at no charge. , Incomplete investigations are still a major concern ...
(Date:6/22/2016)... 22, 2016 Research and Markets has announced ... report to their offering. ... from $29.3 billion in 2013. The market is expected to grow ... 2015 to 2020, increasing from $50.6 billion in 2015 to $96.6 ... during the forecast period (2015 to 2020) are discussed. As well, ...
(Date:6/22/2016)... Washington, USA (PRWEB) , ... June 21, 2016 , ... ... and without cutting into the tissue — promise to enable both compact, wearable devices ... and from even deeper under the skin. , Recent work and visionary future directions ...
Breaking Biology Technology:
(Date:6/9/2016)... attendance control systems is proud to announce the introduction of fingerprint attendance control software, ... employees are actually signing in, and to even control the opening of doors. ... ... ... Photo - http://photos.prnewswire.com/prnh/20160609/377487 ...
(Date:6/3/2016)... 3, 2016 Das ... Nepal hat ein 44 ... geprägter Kennzeichen, einschließlich Personalisierung, Registrierung und IT-Infrastruktur, ... Produktion und Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte ... Januar teilgenommen, aber Decatur wurde als konformste ...
(Date:6/2/2016)... June 2, 2016 Perimeter Surveillance ... Unmanned Systems, Physical Infrastructure, Support & Other Service  ... visiongain offers comprehensive analysis of the global ... will generate revenues of $17.98 billion in 2016. ... Inc, a leader in software and hardware technologies for ...
Breaking Biology News(10 mins):